Search

Displaying results 5611 - 5620 of 10000 in total
  1. Drug

    SIG-007

    go.drugbank.com/drugs/DB17710
    Experimental

    SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. … Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153]

  2. Drug

    SR 121463

    go.drugbank.com/drugs/DB05455
    Investigational

    SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).

  3. Drug

    Bordetella pertussis pertactin antigen

    go.drugbank.com/drugs/DB10789
    ApprovedInvestigational

    Bordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].

    Mixtures: 3 ANTIGEN, BOOSTRIX® VACUNA ADSORBIDA DTPA
  4. Drug

    Elocalcitol

    go.drugbank.com/drugs/DB06194
    Experimental

    Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).

    Categories: Vitamin D and Analogues
  5. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

    Categories: 4-Quinolones, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  7. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients.

    Categories: Adrenergic beta-1 Receptor Agonists, Heterocyclic Compounds, 1-Ring
  8. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Vitamin K Antagonists
  9. Drug

    Iclaprim

    go.drugbank.com/drugs/DB06358
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.